What is Immunovant Inc Quarterly Revenue?

Immunovant Inc Quarterly Revenue Immunovant Inc Jun-2026 Quarterly Revenue is $0 Million which is growth of 0% YoY.

What is Immunovant Inc Quarterly Net Profit?

Immunovant Inc Quarterly Net Profit Immunovant Inc Jun-2026 Quarterly Net Profit is $-153 Million which is growth of -27.0% YoY.

What is Immunovant Inc Annual Revenue?

Immunovant Inc Annual Revenue Immunovant Inc Annual Revenue is $0 Million which is growth of 0% YoY.

What is Immunovant Inc Annual Net Profit?

Immunovant Inc Annual Net Profit Immunovant Inc Annual Net Profit is $-506 Million which is growth of -22.2% YoY.

What is Immunovant Inc Total Shareholders Fund?

Immunovant Inc Total Shareholders Fund Immunovant Inc Mar-2026 Total Shareholders Fund is $853 Million which is growth of 20.5% YoY.

What is Immunovant Inc Total Assets?

Immunovant Inc Total Assets Immunovant Inc Mar-2026 Total Assets is $957 Million which is growth of 23.3% YoY.

What is Immunovant Inc Book Value Per Share?

Immunovant Inc Book Value Per Share Immunovant Inc Book Value Per Share is $4 which is growth of 2.0% YoY.

What is Immunovant Inc ROE?

Immunovant Inc ROE Immunovant Inc ROE is -65% which is growth of 2.4% YoY.

What is Immunovant Inc Cash From Operating Activity?

Immunovant Inc Cash From Operating Activity Immunovant Inc Cash From Operating Activity is $-407 Million which is growth of -8.4% YoY.

What is Immunovant Inc Net Cash Flow?

Immunovant Inc Net Cash Flow Immunovant Inc Net Cash Flow is $188 Million which is growth of 142.0% YoY.

Immunovant Inc

XNAS: IMVT

Download real time

-0.37(-1.10%)

26.79% Fall from 52W High

1.1M

XNAS Volume

XNAS 05 Oct, 2026 5:30 PM (EDT)

Portfolio

Alert

My Notes

Immunovant Inc quarterly and annual earnings report: results, revenue, profit, P&L, balance sheet, cash flow, financial ratios, revenue mix, peer comparison, and financial documents

View Charts

Immunovant Inc quarterly results: revenue, profit, and P&L – 13 quarter history

Nested row level

Base Level

Reporting Type

Originally Reported

Cell Data

Actual

Table Settings

YoY & New to Old

Nested row level

Base Level

Export

NEUTRAL
Quarterly Revenue Immunovant Inc Jun-2026 Quarterly Revenue is $0 Million which is growth of 0% YoY.
NEGATIVE
Quarterly Net Profit Immunovant Inc Jun-2026 Quarterly Net Profit is $-153 Million which is growth of -27.0% YoY.

Immunovant Inc, Earnings Report - Quarterly Results, standalone, All financials are in USD Million and price data in USD
Indicator	Jun '26	Mar '26	Dec '25	Sep '25	Jun '25	Mar '25	Dec '24	Sep '24	Jun '24	Mar '24	Dec '23	Sep '23	Jun '23
SR_Q Operating Rev.
CostOfRevenue_Q Cost Of Rev.	-	-	-	-	-	-	-	-	-	-	-	-	-
GrossProfit_Q Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-
OEXPNS_Q Operating Exp. ⌄	160.3	159.6	114.4	131.8	127.2	113.8	114.3	115.7	94.3	80.9	61.6	61.8	66
AdminAndSellingExpenses_Q Admin Plus Selling Exp.	17.7	17.3	15.4	17.5	26	20.2	19.8	18.5	18.8	14.8	13.2	13.8	15.4
ResearchAndDevlopmentExpenses_Q RnD Exp.	142.6	142.3	98.9	114.3	101.2	93.7	94.5	97.3	75.5	66.1	48.3	48	50.6
OP_Q Operating Profit	-160.3	-159.6	-114.4	-131.8	-127.2	-113.8	-114.3	-115.7	-94.3	-80.9	-61.6	-61.8	-66
NetNonOperIntIncExp_Q Net Non Operations Interest Incuding Expenses ⌄	7.1	8.1	5.3	5.6	6.3	6.9	4.6	6.1	7.2	8.4	8.9	3.6	4.1
Others_Q Other Interest Earned	7.1	8.1	5.3	5.6	6.3	6.9	4.6	6.1	7.2	8.4	8.9	3.6	4.1
IntExpNonOperating_Q Interest Exp. Non Operating	-	-	-	-	-	-	-	-	-	-	-	-	-
PBT_Q Profit Before Tax	-153.2	-150.7	-109.1	-125.9	-119.7	-105.9	-111	-109	-87.1	-75.1	-51.5	-58.2	-74
TAX_Q Tax		-2.8	1.6	0.6	0.9	0.6	0.2	0.1	0.1	0.2	-0.1	0.5	-0
NICommonStockholders_Q Net Income Common Stockholders ⌄	-153.2	-147.9	-110.6	-126.5	-120.6	-106.5	-111.1	-109.1	-87.2	-75.3	-51.4	-58.7	-73.9
NP_Q Net Profit	-153.2	-147.9	-110.6	-126.5	-120.6	-106.5	-111.1	-109.1	-87.2	-75.3	-51.4	-58.7	-73.9
NIIncludingNoncontrollingInterests_Q Net Income Including Non controlling Interests	-153.2	-147.9	-110.6	-126.5	-120.6	-106.5	-111.1	-109.1	-87.2	-75.3	-51.4	-58.7	-73.9
DilutedNIAvailtoComStockholders_Q Diluted NI Avail to Com Stockholders Ann.	-153.2	-147.9	-110.6	-126.5	-120.6	-106.5	-111.1	-109.1	-87.2	-75.3	-51.4	-58.7	-73.9
EPS_Q Basic EPS	-0.8	-0.7	-0.6	-0.7	-0.7	-0.6	-0.8	-0.7	-0.6	-0.5	-0.4	-0.5	-0.6
AfterDilutedEPS_Q Diluted EPS After ExtraOrdinary	-0.8	-0.7	-0.6	-0.7	-0.7	-0.6	-0.8	-0.7	-0.6	-0.5	-0.4	-0.5	-0.5
SHARE_Q Number Of Shares End	205.6	203.4	181.5	173.6	170.9	166.6	146.9	146.5	146.1	145.7	144.5	131.2	130.5
NIContinuingDiscontinuedOper_Q Net Income Continuing Discontinued Operations	-153.2	-147.9	-110.6	-126.5	-120.6	-106.5	-111.1	-109.1	-87.2	-75.3	-51.4	-58.7	-73.9
NormalizedIncome_Q Normalized Income	-153.2	-147.9	-110.6	-126.5	-120.6	-106.5	-111.1	-109.1	-87.2	-75.3	-51.4	-58.7	-61.4
InterestIncome_Q Interest Income	7.1	8.1	5.3	5.6	6.3	6.9	4.6	6.1	7.2	8.4	8.9	3.6	4.1
INT_Q Interest	-	-	-	-	-	-	-	-	-	-	-	-	-
NetInterestIncome_Q Net Interest Income	7.1	8.1	5.3	5.6	6.3	6.9	4.6	6.1	7.2	8.4	8.9	3.6	4.1
EBIT_Q EBIT	-160.3	-159.6	-114.4	-131.8	-127.2	-113.8	-114.3	-115.7	-94.3	-80.9	-61.6	-61.8	-66
EBITDA_Q EBITDA	-160.2	-159.5	-114.3	-131.7	-127.1	-113.7	-114.2	-115.7	-94.2	-80.8	-61.5	-61.7	-65.9
ReconciledCostOfRevenue_Q Reconciled Cost Of Rev.	-	-	-	-	-	-	-	-	-	-	-	-	-
ReconciledDepreciation_Q Reconciled Depr.	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
ProfitLossFromContinuingOperations_Q Profit From Continuing Operations	-153.2	-147.9	-110.6	-126.5	-120.6	-106.5	-111.1	-109.1	-87.2	-75.3	-51.4	-58.7	-73.9
NormalizedEBITDA_Q Normalized EBITDA	-160.2	-159.5	-114.3	-131.7	-127.1	-113.7	-114.2	-115.7	-94.2	-80.8	-61.5	-61.7	-53.4

*All financials are in USD Million and price data in USD

Add metric to table

Search...

Immunovant Inc competitor comparison and performance snapshot within industry

Immunovant Inc annual results: revenue, profit, P&L, and margins as of Mar 2026 – 11 year history

Nested row level

Base Level

Reporting Type

Originally Reported

Cell Data

Actual

Table Settings

YoY & New to Old

CAGR Columns

Select...

Nested row level

Base Level

Export

NEUTRAL
Annual Revenue Immunovant Inc Annual Revenue is $0 Million which is growth of 0% YoY.
NEGATIVE
Annual Net Profit Immunovant Inc Annual Net Profit is $-506 Million which is growth of -22.2% YoY.

Immunovant Inc, Earnings Report - Annual Results, standalone, All financials are in USD Million and price data in USD
Indicator	CAGR 3 Yrs	CAGR 5 Yrs	TTM	Mar '26	Mar '25	Mar '24	Mar '23	Mar '22	Mar '21	Mar '20	Dec '18
SR_A Total Rev. Ann. ⌄	-	-									-
TotalOperatingRevenues_A Operating Rev. Ann.	-	-									-
CostOfRevenue_A Cost Of Rev. Ann.	-	-		-	-	-	-	-	-	-	-
GrossProfit_A Gross Profit Ann.	-	-		-	-	-	-	-	-	-	-
OEXPNS_A Operating Exp. Ann.	36.8%	37.6%	566	532.9	438.2	270.2	208.3	156	108.1	66.1
OP_A Operating Profit Ann.	-	-	-566	-532.9	-438.2	-270.2	-208.3	-156	-108.1	-66.1
NetNonOperIntIncExp_A Net Non Operations Interest Incuding Expenses Ann, ⌄	49.3%	-	26.1	25.3	24.7	25	7.6	-		-0.6	-
Others_A Other Interest Earned Ann.	49.3%	-	26.1	25.3	24.7	25	7.6	-	-	-	-
IntExpNonOperating_A Interest Exp. Non Operating Ann.	-	-		-	-	-	-	-		0.6	-
OtherExpenses_A Other Exp. Ann.	-	49%		2.2	0.5	-13.5	-10.3	-0.8	0.3	0.4	-
PBT_A PBT Ann.	-	-	-538.9	-505.4	-413	-258.8	-211	-156.8	-107.8	-66.3	-
TAX_A Tax Ann.	-	-	-0.7	0.2	0.9	0.6	0	-0.1	-0.4	0.1	-
NICommonStockholders_A Net Income Common Stockholders Ann. ⌄	-	-	-538.2	-505.6	-413.8	-259.3	-211	-156.7	-107.4	-66.4	-
NP_A Net Profit Ann.	-	-	-538.2	-505.6	-413.8	-259.3	-211	-156.7	-107.4	-66.4	-
NIIncludingNoncontrollingInterests_A Net Income Including Non controlling Interests Ann.	-	-	-538.2	-505.6	-413.8	-259.3	-211	-156.7	-107.4	-66.4	-
DilutedNIAvailtoComStockholders_A Diluted NI Avail to Com Stockholders Ann.	-	-	-538.2	-505.6	-413.8	-259.3	-211	-156.7	-107.4	-66.4	-
EPS_A EPS Ann.	-	-		-2.8	-2.7	-1.9	-1.7	-1.4	-1.2	-1.5	-
DilutedEPS_A Diluted EPS Ann.	-	-		-2.8	-2.7	-1.9	-1.7	-1.4	-1.2	-1.5	-
SHARE_Q Number Of Shares End	16%	15.8%		203.4	166.6	145.7	130.3	116.4	97.8	54.6	-
TotalExpenses_A Total Exp. Ann.	36.8%	37.6%		532.9	438.2	270.2	208.3	156	108.1	66.1	-
NIContinuingDiscontinuedOper_A Net Income Continuing Discontinued Operations Ann.	-	-	-538.2	-505.6	-413.8	-259.3	-211	-156.7	-107.4	-66.4	-
NormalizedIncome_A Normalized Income Ann.	-	-	-538.2	-505.6	-413.8	-249.5	-201	-156.7	-107.4	-66.4	-
InterestIncome_A Interest Income Ann.	49.3%	-	26.1	25.3	24.7	25	7.6	-	-	-	-
INT_A Interest Ann.	-	-		-	-	-	-	-		0.6	-
EBITDA_A EBITDA Ann.	-	-	-565.6	-532.5	-437.8	-270	-208.1	-155.9	-107.7	-65.6	-
ReconciledCostOfRevenue_A Reconciled Cost Of Rev. Ann.	-	-		-	-	-	-	-	-	-	-
ReconciledDepreciation_A Reconciled Depr. Ann.	26%	32%	0.4	0.4	0.4	0.2	0.2	0.1	0.1	0	-
ProfitLossFromContinuingOperations_A Profit From Continuing Operations Ann.	-	-	-538.2	-505.6	-413.8	-259.3	-211	-156.7	-107.4	-66.4	-
NormalizedEBITDA_A Normalized EBITDA Ann.	-	-	-565.6	-532.5	-437.8	-257.5	-198.1	-155.9	-107.7	-65.6	-

*All financials are in USD Million and price data in USD

Add metric to table

Search...

Operating Exp. Ann.

1Y CHG

21.6%

2Y CAGR

40.4%

3Y CAGR

36.8%

5Y CAGR

37.6%

Operating Expenses Annual Cr growth is lower than historical averages.

Immunovant Inc balance sheet as of Mar 2026: assets, liabilities, reserves, and borrowings – 11 year history

Nested row level

Base Level

Reporting Type

Originally Reported

Cell Data

Actual

Table Settings

YoY & New to Old

CAGR Columns

Select...

Nested row level

Base Level

Export

POSITIVE
Total Shareholders Fund Immunovant Inc Mar-2026 Total Shareholders Fund is $853 Million which is growth of 20.5% YoY.
POSITIVE
Total Assets Immunovant Inc Mar-2026 Total Assets is $957 Million which is growth of 23.3% YoY.

Immunovant Inc, Balance Sheet, standalone, All financials are in USD Million and price data in USD
Indicator	CAGR 3 Yrs	CAGR 5 Yrs	Mar '26	Mar '25	Mar '24	Mar '23	Mar '22	Mar '21	Mar '20	Dec '18
TA_A Total Assets Ann. ⌄	33.1%	18.3%	957	776.2	666.4	405.8	515.6	412.5	109.4	0.4
CA_A Total Current Assets Ann.	32.9%	18.3%	948.8	767.7	665.8	404.3	512.9	409	109.1	0.3
CashEquivalentsShortTermInvestments_A Cash Equivalents and Short Term Investments Ann.	33.8%	17.7%	902.1	714	635.4	376.5	493.8	400.2	100.6	0.3
Receivables_A Change In Account Receivables Ann.	64.4%	46.1%	4	2.5	5.5	0.9	12.9	0.6	3	-
Inventories_A Inventories Ann.	-	-	-	-	-	-	-	-	-	-
OtherCurrentAssets_A Other Current Assets Ann.	16.7%	38.8%	42.8	51.2	24.9	26.9	6.3	8.3	5.5	-
TotalNonCurrentAssets_A Total Non Current Assets Ann.	76.2%	18.6%	8.2	8.6	0.6	1.5	2.6	3.5	0.3	0.1
NetPPE_A Net PPE Ann.	-30.7%	-32.2%	0.5	0.9	0.6	1.5	2.6	3.5	0.1	-
InvestmentsAndAdvances_A Investments & Advances Ann.	-	-	-	-	-	-	-	-	-	-
OtherNonCurrentAssets_A Other Non Current Assets Ann.	-	-	7.7	7.6	-	-	-	-	-	-
TotalLiabilitiesNetMinorityInterest_A Total Liabilities Net Minority Interest Ann. ⌄	34.1%	37.8%	104.4	68.8	48.6	43.3	45.7	21	15.3	0.4
CL_A Total Current Liabilities Ann.	34.1%	40.9%	104.4	68.8	48.6	43.3	44.5	18.8	15.3	0.4
PayablesAndAccruedExpenses_A Payables & Accrued Exp.s Ann.	36.3%	43.3%	87.6	53.1	33.7	34.6	38.9	14.5	15.3	0.1
CurrentDebtCapLeaseObligation_A Current Debt Cap Lease Obligation Ann.	-56.3%	-39.2%	0.1	0.1	0.1	1.2	1.2	1.2	-	0.3
CurrentDeferredLiabilities_Q Current Deferred Liabilities	-	-	-	-	-	-	-	-	-	-
OtherCurrentLiabilities_A Other Current Liabilities Ann.	-	-	-	-	-	-	-	-	-	-
TotalNonCurrentLiabilities_A Total Non Current Liabilities Ann.	-	-				0.1	1.2	2.2
LongTermDebtAndCapitalLeaseObligation_Q LT Debt & Capital Lease Obligation	-	-	-	-		0.1	1.2	2.2	-	-
TradeandOtherPayablesNonCurrent_A Trade & Other Payables Non Current Ann.	-	-	-	-	-	-	-	-	-	-
TotalDeferredCreditsAndOtherNonCurrentLiabilities_A Total Deferred Credits & Other Non Current Liabilities Ann.	-	-	-	-	-	-	-	-	-	-
TotalShareHoldersFunds_A Total ShareHolders Funds Ann. ⌄	33%	16.8%	852.6	707.5	617.8	362.5	469.8	391.5	94.1	0
EQCAP_A Equity Share Capital Ann.	33%	16.8%	852.6	707.5	617.8	362.5	469.8	391.5	94.1	0
CapitalStock_A Capital Stock Ann.	-	-	0	0	0	0	0	0	0
RetainedEarnings_A Retained Earnings Ann.	-	-	-1,745.1	-1,239.5	-825.7	-566.4	-355.4	-198.7	-91.2
GainsLossesNotAffectingRetainedEarnings_A Gains Losses Not Affecting Retained Earnings Ann.	-8%	-	0.7	1.5	1.9	0.9	0.4	-0.3	-0	-
TotalCapitalization_A Total Capitalization Ann.	33%	16.8%	852.6	707.5	617.8	362.5	469.8	391.5	94.1	0
TangibleAssets_A Tangible Assets Ann.	33%	16.8%	852.6	707.5	617.8	362.5	469.8	391.5	94.1	0
WC_A Working Capital Ann.	32.7%	16.7%	844.4	698.9	617.2	361	468.4	390.2	93.8	-0.1
InvestedCapital_A Invested Capital Ann.	33%	16.8%	852.6	707.5	617.8	362.5	469.8	391.5	94.1	0.3
TangibleBookValue_A Tangible Book Value Ann.	33%	16.8%	852.6	707.5	617.8	362.5	469.8	391.5	94.1	0
Borrowings_A Borrowings Ann.	-56.3%	-50.6%	0.1	0.1	0.1	1.2	2.4	3.4	-	0.3
NetDebt_A Net Debt Ann.	-	-	-	-	-	-	-	-	-	-
ShareIssued_A Share Issued Ann.	16.1%	15.8%	203.9	170.1	145.6	130.3	116.5	98	56.5	14.4
SHARE_Q Number Of Shares End	16%	15.8%	203.4	166.6	145.7	130.3	116.4	97.8	54.6	-

*All financials are in USD Million and price data in USD

Add metric to table

Search...

Total Assets Ann.

1Y CHG

23.3%

2Y CAGR

19.8%

3Y CAGR

33.1%

5Y CAGR

18.3%

Total Assets Annual growth is stable compared to historical averages.

Total Current Liabilities Ann.

1Y CHG

51.7%

2Y CAGR

46.6%

3Y CAGR

34.1%

5Y CAGR

40.9%

Total Current Liabilities Annual Cr growth is stable compared to historical averages.

Total ShareHolders Funds Ann.

1Y CHG

20.5%

2Y CAGR

17.5%

3Y CAGR

33%

5Y CAGR

16.8%

Total ShareHolders Funds Annual growth is stable compared to historical averages.

Immunovant Inc ROE, ROCE, book value, and debt-to-equity ratio as of Mar 2026 – 11 year history

Nested row level

Base Level

Reporting Type

Originally Reported

Cell Data

Actual

Table Settings

YoY & New to Old

CAGR Columns

Select...

Nested row level

Base Level

Export

POSITIVE
Book Value Per Share Immunovant Inc Book Value Per Share is $4 which is growth of 2.0% YoY.
POSITIVE
ROE Immunovant Inc ROE is -65% which is growth of 2.4% YoY.

Immunovant Inc, Ratios, standalone, All financials are in USD Million and price data in USD
Indicator	CAGR 3 Yrs	CAGR 5 Yrs	Mar '26	Mar '25	Mar '24	Mar '23	Mar '22	Mar '21	Mar '20	Dec '18
ROA_A RoA Ann. %	-	-	-58.34%	-57.37%	-48.37%	-45.79%	-33.78%	-41.17%	-121.02%	-
ROE_A ROE Ann. %	-	-	-64.82%	-62.46%	-52.91%	-50.69%	-36.39%	-44.25%	-141.11%	-
ROIC_Q ROIC %	-	-	-16.9	-21.1	-12.6	-16.1	-9.6	-6.9	-20	-
OPMPCT_A OPM Ann. %	-	-	-	-	-	-	-	-	-	-
NBTO_A Inventory Turnover Ratio Ann.	-	-	-	-	-	-	-	-	-	-
ASETTO_A Asset Turnover Ann. %	-	-	-	-	-	-	-	-	-	-
WCTO_A Working Capital Turnover Ann.	-	-								-
QuickRatio_A Quick Ratio Ann.	0%	-16.5%	8.7	10.4	13.2	8.7	11.4	21.4	6.8	0.9
CRATIO_A Current Ratio Ann.	-0.7%	-16%	9.1	11.2	13.7	9.3	11.5	21.8	7.1	0.9
IC_A Interest Coverage Ratio Ann.	-	-	-	-	-	-	-	-	-105.1	-
LTDE_A LT Debt To Equity Ann.	-	-	-	-	-			0	-	-

*All financials are in USD Million and price data in USD

Add metric to table

Search...

Current Ratio Ann.

1Y CHG

-18.7%

2Y CAGR

-18.5%

3Y CAGR

-0.7%

5Y CAGR

-16%

Current Ratio Annual is falling faster than historical averages.

Immunovant Inc cash flow: net, operating, investing, and financing flows as of Mar 2026 – 11 year history

Nested row level

Base Level

Reporting Type

Originally Reported

Cell Data

Actual

Table Settings

YoY & New to Old

CAGR Columns

Select...

Nested row level

Base Level

Export

NEGATIVE
Cash From Operating Activity Immunovant Inc Cash From Operating Activity is $-407 Million which is growth of -8.4% YoY.
POSITIVE
Net Cash Flow Immunovant Inc Net Cash Flow is $188 Million which is growth of 142.0% YoY.

Immunovant Inc, Cash Flow, standalone, All financials are in USD Million and price data in USD
Indicator	CAGR 3 Yrs	CAGR 5 Yrs	Mar '26	Mar '25	Mar '24	Mar '23	Mar '22	Mar '21	Mar '20	Dec '18
CFO_A Cash from Operating Act. Ann. ⌄	-	-	-407.3	-375.9	-214.2	-188.2	-106.1	-83.3	-53.4	-
ProfitLossFromContinuingOperations_A Profit From Continuing Operations Ann.	-	-	-505.6	-413.8	-259.3	-211	-156.7	-107.4	-66.4	-
DepreciationAmortizationDepletion_A Depreciation Amortization Depletion Ann.	26%	32%	0.4	0.4	0.2	0.2	0.1	0.1	0	-
DepreciationAndAmortization_A Depreciation And Amortization Ann.	26%	32%	0.4	0.4	0.2	0.2	0.1	0.1	0	-
DeferredTax_A Deferred Tax Ann.	-	-	-	-	-	-	-	-	-	-
DeferredIncomeTax_A Deferred Income Tax Ann.	-	-	-	-	-	-	-	-	-	-
EmployeesStockOptions_A ESOPs Ann.	19.9%	24.3%	55.7	49.5	41.1	32.3	34.2	18.8	7	-
OtherNonCashItems_A Other Non Cash Items Ann.	-55%	-35.6%	0.1	0.1	1.1	1.1	1.1	0.9	-	-
ChangeInWorkingCapital_A Change In Working Capital Ann.	-	55.7%	42.1	-12	2.6	-10.9	15.1	4.6	4.8	-
ChangeInReceivables_A Change In Receivables Ann.	-	-	-1.4	3	-4.6	12.2	-11.7	2.5	-0.1	-
ChangeInInventory_A Change In Inventory Ann.	-	-	-	-	-	-	-	-	-	-
ChangePayablesAccruedExpense_A Change Payables Accrued Expense Ann.	-	43.5%	34.7	19.9	6.8	-1.4	25.9	5.7	7.7	-
ChangeInOtherCurrentAssets_A Change In Other Current Assets Ann.	-	-	0.1	-7.7	-	-	-	-	-	-
ChangeInOtherCurrentLiabilities_A Change In Other Current Liabilities Ann.	-	-	-0.1	-0.1	-1.2	-1.2	-1.2	-0.8	-	-
ChangeInOtherWorkingCapital_A Change In Other Working Capital Ann.	-	-	-	-	-	-	-	-	-	-
CFI_A Cash from Investing Act. Ann. ⌄	-	-	-0	-0.8	-0.4	-0.2	-0.3	-0.2	-0	-
NetPPEPurchaseAndSale_A Net PPE Purchase & Sale Ann.	-	-	-0	-0.8	-0.4	-0.2	-0.3	-0.2	-0	-
PurchaseOfPPE_A Purchase Of PPE Ann.	-	-	-0	-0.8	-0.4	-0.2	-0.3	-0.2	-0	-
NetBusinessPurchaseAndSale_A Net Business Purchase & Sale Ann.	-	-	-	-	-	-	-	-	-	-
PurchaseOfBusiness_A Purchase Of Business Ann.	-	-	-	-	-	-	-	-	-	-
PurchaseOfInvestment_A Purchase Of Investment Ann.	-	-	-	-	-	-	-	-	-	-
SaleOfInvestment_A Sale Of Investment Ann.	-	-	-	-	-	-	-	-	-	-
NetOtherInvestingChanges_A Net Other Investing Changes Ann.	-	-	-	-	-	-	-	-	-	-
CFA_A Cash from Financing Act. Ann. ⌄	103.3%	9.2%	595.8	454.5	472.4	70.9	200.1	383.1	147	-
NetIssuancePaymentsOfDebt_A Net Issuance Payments Of Debt Ann.	-	-	-	-	-	-		-3.2	37.9	-
NetLongTermDebtIssuance_A Net Long Term Debt Issuance Ann.	-	-	-	-	-	-		-	-	-
NetShortTermDebtIssuance_A Net ST Debt Issuance Ann.	-	-	-	-	-	-	-	-3.2	37.9	-
NetCommonStockIssuance_A Net Common Stock Issuance Ann.	97.6%	11.2%	544.2	450	472.8	70.5		319.8		-
CommonStockIssuance_A Common Stock Issuance Ann.	97.6%	11.2%	544.2	450	472.8	70.5		319.8		-
CommonStockPayments_A Common Stock Payments Ann.	-	-	-	-	-	-	-	-	-	-
dividend_1Y_actual Dividend 1year	-	-
DividendPerShare_A Dividend Per Share Ann.	-	-	-	-	-	-	-	-	-	-
NetOtherFinancingCharges_A Net Other Financing Charges Ann.	-	-	-0.5	-0.3	-6	-0.3	200.1	-0.1	109.1	-
CashAndCashEquivalentEndOfYear_A Cash Plus Cash Eqv. End Of Year Ann.	33.8%	17.7%	902.1	714	635.4	376.5	493.8	400.2	100.6	-
NetIncDecInCashAndCashEquivalents_A Net Increase In Cash Plus Cash Eqv.s Ann.	-	-8.9%	188.4	77.9	257.8	-117.5	93.8	299.6	93.6	-
CashAndCashEquivalentBeginOfYear_A Cash Plus Cash Eqv. Begin Of Year Ann.	13.1%	48%	714	635.4	376.5	493.8	400.2	100.6	7	-
IncomeTaxPaidSupplementalData_A Income Tax Paid Supplemental Data Ann.	-	64.4%	2.4	1.2	0.5	-		0.2	-	-
InterestPaidSupplementalData_A Interest Paid Supplemental Data Ann.	-	-	-	-	-	-	-	-	-	-
CapitalExpenditure_A Capex Ann.	-	-	-0	-0.8	-0.4	-0.2	-0.3	-0.2	-0	-
IssuanceOfCapitalStock_A Issuance Of Capital Stock Ann.	97.6%	11.2%	544.2	450	472.8	70.5		319.8		-
IssuanceOfDebt_A Issuance Of Debt Ann.	-	-	-	-	-	-	-		42.9	-
RepaymentOfDebt_A Repayment Of Debt Ann.	-	-	-	-	-	-		-3.2	-5	-
RepurchaseOfCapitalStock_A Repurchase Of Capital Stock Ann.	-	-	-	-	-	-	-	-	-	-
FreeCashFlow_A Free Cash Flow Ann.	-	-	-407.3	-376.6	-214.6	-188.4	-106.4	-83.5	-53.4	-

*All financials are in USD Million and price data in USD

Add metric to table

Search...

Cash from Financing Act. Ann.

1Y CHG

31.1%

2Y CAGR

12.3%

3Y CAGR

103.3%

5Y CAGR

9.2%

Cash from Financing Annual Activity growth is stable compared to historical averages.

Quarterly
Competitors/Peers
Annual
Balance Sheet
Ratios
Cash Flow

26.79% Fall from 52W High

Immunovant Inc quarterly and annual earnings report: results, revenue, profit, P&L, balance sheet, cash flow, financial ratios, revenue mix, peer comparison, and financial documents

Immunovant Inc - Earnings Report - Quarterly Results

Immunovant Inc quarterly results: revenue, profit, and P&L – 13 quarter history

Quarterly Revenue Immunovant Inc Jun-2026 Quarterly Revenue is $0 Million which is growth of 0% YoY.

Quarterly Net Profit Immunovant Inc Jun-2026 Quarterly Net Profit is $-153 Million which is growth of -27.0% YoY.

Immunovant Inc - Competitors/Peers

Immunovant Inc competitor comparison and performance snapshot within industry

Immunovant Inc - Earnings Report - Annual Results

Immunovant Inc annual results: revenue, profit, P&L, and margins as of Mar 2026 – 11 year history

Annual Revenue Immunovant Inc Annual Revenue is $0 Million which is growth of 0% YoY.

Annual Net Profit Immunovant Inc Annual Net Profit is $-506 Million which is growth of -22.2% YoY.

Immunovant Inc - Balance Sheet

Immunovant Inc balance sheet as of Mar 2026: assets, liabilities, reserves, and borrowings – 11 year history

Total Shareholders Fund Immunovant Inc Mar-2026 Total Shareholders Fund is $853 Million which is growth of 20.5% YoY.

Total Assets Immunovant Inc Mar-2026 Total Assets is $957 Million which is growth of 23.3% YoY.

Immunovant Inc - Ratios

Immunovant Inc ROE, ROCE, book value, and debt-to-equity ratio as of Mar 2026 – 11 year history

Book Value Per Share Immunovant Inc Book Value Per Share is $4 which is growth of 2.0% YoY.

ROE Immunovant Inc ROE is -65% which is growth of 2.4% YoY.

Immunovant Inc - Cash Flow

Immunovant Inc cash flow: net, operating, investing, and financing flows as of Mar 2026 – 11 year history

Cash From Operating Activity Immunovant Inc Cash From Operating Activity is $-407 Million which is growth of -8.4% YoY.

Net Cash Flow Immunovant Inc Net Cash Flow is $188 Million which is growth of 142.0% YoY.